3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Colorectal Neoplasms
3
Lung Neoplasms
2
Head and Neck Neoplasms
2
Fibromatosis, Gingival, 2
2
Uterine Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Lethal Congenital Contracture Syndrome 2
1
Kidney Neoplasms
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Cholangiocarcinoma
1
Breast Neoplasms
1
Bile Duct Neoplasms
1
Adenocarcinoma
1
Interventions
Carboplatin
12
Pemetrexed
11
pembrolizumab
10
Paclitaxel
6
Cisplatin
6
Erlotinib Hydrochloride
5
Docetaxel
5
Nivolumab
4
Gefitinib
4
spartalizumab
3
osimertinib
3
Gemcitabine
3
EC145
3
Crizotinib
3
Afatinib
3
technetium 99m etarfolatide
2
pralsetinib
2
fludarabine
2
cemiplimab
2
brigatinib
2
alpha-2'-deoxythioguanosine
2
aldesleukin
2
Vinorelbine
2
Radiotherapy
2
Quality of Life
2
MORAb-202
2
Immunotherapy
2
Drug Therapy
2
Cyclophosphamide
2
Blood Specimen Collection
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
seribantumab
×
Thoracic
×
Clear all
NCT02387216
2021-10-12
SHERLOC
Elevation Oncology
Phase 2
Terminated
153 enrolled
19 charts